Bet on drug resistance

Jeff Settleman ()
Additional contact information
Jeff Settleman: Jeff Settleman is at Calico Life Sciences, South San Francisco, California 94080, USA.

Nature, 2016, vol. 529, issue 7586, 289-290

Abstract: Inhibitors of the BET bromodomain proteins are promising cancer therapeutics, but tumour cells are likely to become resistant to these drugs. Anticipated mechanisms of resistance have now been described. See Letter p.413

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature16863 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:529:y:2016:i:7586:d:10.1038_nature16863

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature16863

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().